Yogesh Batra
All India Institute of Medical Sciences
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Yogesh Batra.
Gastrointestinal Endoscopy | 2004
Pramod Kumar Garg; Tandon Rk; Vineet Ahuja; Govind K. Makharia; Yogesh Batra
BACKGROUND Mechanical lithotripsy is used to break large bile duct stones. This study investigated the predictors of unsuccessful mechanical lithotripsy. METHODS Consecutive patients with bile duct stones underwent endoscopic retrograde cholangiography, sphincterotomy, and basket removal of stones. Mechanical lithotripsy was performed for stones of large size (>15 mm diameter) that precluded extraction intact. Success was defined as complete clearance of the duct. Various predictive factors, including size and number of stones, stone impaction, serum bilirubin, presence of cholangitis, and bile duct diameter were analyzed in relation to the success or failure of lithotripsy. RESULTS A total of 669 patients underwent endoscopic retrograde cholangiography for suspected choledocholithiasis, which was found in 401 patients. Of the latter patients, 87 had large stones that required mechanical lithotripsy. Lithotripsy was successful in 69 (79%) patients. Impaction of the stone(s) in the bile duct was the only significant factor that predicted failure of lithotripsy and consequent failure of bile duct clearance. Other factors, including stone size, were not significant. CONCLUSIONS Mechanical lithotripsy is successful in about 79% of patients with large bile duct stones. The only significant factor that predicts failure of mechanical lithotripsy is stone impaction in the bile duct.
Journal of Gastroenterology and Hepatology | 2005
Yogesh Batra; Sujoy Pal; Usha Dutta; Premal Desai; Pramod Kumar Garg; Govind K. Makharia; Vineet Ahuja; Pande Gk; Peush Sahni; Tushar Kanti Chattopadhyay; Tandon Rk
Background: Gallbladder cancer (GBC) is one of the most common gastrointestinal malignancies. The data regarding GBC are, however, limited.
Journal of Gastroenterology and Hepatology | 2003
Subrat K. Acharya; Yogesh Batra; Bharati Bhatkal; Bandana Ojha; Kuldeep Kaur; Siddarth Hazari; Anoop Saraya; Subrat Kumar Panda
Background: Universal vaccination against hepatitis A virus (HAV) has been recommended for children because of the changing epidemiological pattern of HAV. Vaccination has also been advised for patients with chronic liver disease as HAV superinfection in these patients can result in severe or even fatal disease. In India, the indications for HAV vaccination are not clear due to contradictory seroepidemiological data in children and lack of data on HAV seroprevalence in patients with chronic liver disease.
Journal of Gastroenterology and Hepatology | 2002
Subrat K. Acharya; Yogesh Batra; Sidhartha Hazari; Choudhury; Subrat Kumar Panda; Siddhartha Dattagupta
Abstract Etiopathogenesis of acute hepatic failure (AHF) in Eastern and Western countries is distinct. In the East hepatitis viruses cause AHF in more than 95% of such cases, while causes of AHF in the West are quite heterogenous. Hepatitis E virus is the major etiological agent of AHF in countries like India where the virus is hyperendemic. Occult HBV infection may also be causing AHF in a sizable proportion of cases in areas where chronic HBV infection frequency is high. Paracetamol causes AHF in about 70% cases in the UK and about 20% cases in USA, whereas in France and Denmark, non‐steroidal anti‐inflammatory drugs are more frequently associated with AHF. Hepatitis B virus causes AHF in about one‐third of cases in the latter two countries.
Bulletin of The World Health Organization | 2002
Yogesh Batra; Bharati Bhatkal; Bandana Ojha; Kuldeep Kaur; Anoop Saraya; Subrat Kumar Panda; Subrat K. Acharya
OBJECTIVES To evaluate the current seroprevalence of antibodies against hepatitis A virus (HAV) in a sample of schoolchildren above 10 years of age and to determine the prevalence of HAV-induced hepatitis in adults at a tertiary care hospital in northern India between January 1992 and December 2000. METHODS Sera from 276 male and 224 female schoolchildren aged 10-17 years were tested for anti-HAV antibodies by enzyme-linked immunosorbent assay. Consecutive patients with a diagnosis of acute viral hepatitis who attended a liver clinic were tested for the serological markers of HAV, hepatitis B Virus, hepatitis C virus, hepatitis D virus, and hepatitis E virus. FINDINGS Of the male and female children, 96.3% and 98.2%, respectively had anti-HAV antibodies in their sera. The prevalence of these antibodies in the age groups 10-12, 13- 14, and 15-17 years were 98.6%, 94.8%, and 98.3% respectively. The frequency of HAV- induced acute viral hepatitis (69/870, 8%) in adults did not show an increasing trend. CONCLUSION Mass HAV vaccination may be unnecessary in northern India because the seroprevalence of protective antibodies against HAV in schoolchildren aged over 10 years remains above 95% and there has been no apparent increase in HAV-induced acute viral hepatitis in adults.
Journal of Gastroenterology and Hepatology | 2004
Sidhartha Hazari; Subrat Kumar Panda; Siddharth Datta Gupta; Yogesh Batra; Rajbir Singh; Subrat K. Acharya
Background and Aim: The purpose of the present study was to evaluate the therapeutic response of north Indian patients with chronic hepatitis C (CH‐C) to two different treatment regimens of interferon and ribavirin.
Oncology | 2009
Shashi Bala Paul; Sreenivasa Baba Chalamalasetty; Sreenivas Vishnubhatla; Kaushal Madan; Shivanand Gamanagatti; Yogesh Batra; Siddhartha Datta Gupta; Subrat Kumar Panda; Subrat K. Acharya
Objective: To study the profile and outcome of therapy for hepatocellular carcinoma (HCC) in India. Methods: Data analysis of HCC patients enrolled in liver clinic between 1990 and 2005. Results: We registered 324 HCC patients [males 284 (88%), mean age 52.4 ± 13.1 years]. The etiology of HCC was: hepatitis B virus 165 (51%), hepatitis C virus 38 (12%), alcohol 20 (6%), combined 31 (10%) and unknown 70 (21%). Serum α-fetoprotein was >400 ng in 36%, portal vein invasion was seen in 40% and distant metastases in 13%. Therapy was offered to 141 (43.5%) patients, but survival data was available in only 130 (93%) of them. Treatment given and median survival time was as follows: surgical resection, 19 months (n = 14); transarterial chemoembolization, 11 months (n = 23); transarterial rhenium therapy, 26 months (n = 7); radiofrequency ablation, 24 months (n = 4); acetic acid ablation, 13 months (n = 17); oral chemotherapy, 26 months (n = 33), and combination therapy, 26 months (n = 32). Vascular invasion, Okuda staging and therapy were independent factors associated with survival. Treated patients had longer median survival compared to untreated ones (16 months vs. 7 months, p < 0.05). Conclusions: Hepatitis B infection is the predominant cause of HCC in India. Serum α-fetoprotein was diagnostic in only one third of our patients. Most patients present late, when curative therapies are not possible. Treated patients had better survival than untreated ones.
Hepatology Research | 2009
Kaushal Madan; Yogesh Batra; Vishnubhatla Sreenivas; Masashi Mizokami; Yasuhito Tanaka; Sreenivasa Baba Chalamalasetty; Subrat Kumar Panda; Subrat K. Acharya
Aims: Association of HBV genotypes (especially A and D) with severity of liver disease is controversial. We studied the influence of HBV genotypes on liver disease severity among Indian patients.
Journal of Gastroenterology and Hepatology | 2004
Kaushal Madan; Yogesh Batra; Subrat Kumar Panda; Siddarth Dattagupta; Siddarth Hazari; Jyotish Kumar Jha; Subrat K. Acharya
Background and Aim: Detection of an asymptomatic rise in the hepatic aminotransferase (ARHA) value has become a distinct and frequent clinical problem. We evaluated a three‐step diagnostic algorithm in such patients for maximum yield.
Journal of Hepatology | 2004
Vikram Bhatia; Yogesh Batra; Subrat K. Acharya